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Abstract: The aim of the current study is to examine the improving effect of Sasa borealis 
stem (SBS) extract extracts on high-fat diet (HFD)-induced hepatic steatosis in rats. To 
determine the hepatoprotective effect of SBS, we fed rats a normal regular diet (ND), HFD, 
and HFD supplemented with 150 mg/kg body weight (BW) SBS extracts for five weeks. 
We found that the body weight and liver weight of rats in the HFD + SBS group were 
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significantly lower than those in the HFD group. Significantly lower serum total cholesterol 
(TC) and triglyceride (TG) concentrations were observed in the SBS-supplemented group 
compared with the HFD group. We also found that the HFD supplemented with SBS group 
showed dramatically reduced hepatic lipid accumulation compared to the HFD alone 
group, and administration of SBS resulted in dramatic suppression of TG, TC in the  
HFD-induced fatty liver. In liver gene expression within the SBS treated group, PPARα 
was significantly increased and SREBP-1c was significantly suppressed. SBS induced a 
significant decrease in the hepatic mRNA levels of PPARγ, FAS, ACC1, and DGAT2. In 
conclusion, SBS improved cholesterol metabolism, decreased lipogenesis, and increased 
lipid oxidation in HFD-induced hepatic steatosis in rats, implying a potential application in 
treatment of non-alcoholic fatty liver disease.  
Keywords: high-fat diet; Sasa borealis stem; hepatic steatosis; hepatic gene expression 
 
1. Introduction 
Obesity-related nonalcoholic fatty liver disease (NAFLD), one of the most common liver diseases, 
is significantly associated with metabolic syndrome, including obesity, dyslipidemia, and insulin 
resistance [1,2]. A hypercaloric dietary habit easily results in increased body weight, serum lipids, and 
hepatic lipid accumulation. Increased liver lipid accumulation causes lipid peroxidation, leading to 
further advancement of liver damage. Accumulation of triglycerides, termed as hepatic steatosis, which 
is characterized by fibrosis and necroinflammation, and can progress to cirrhosis and terminal liver 
failure, has been proposed as an indication of more severe liver disease [3]. Of particular importance, 
hepatic steatosis is always coupled with other diseases, i.e., obesity, diabetes, and hyperlipidemia [4]. 
Therefore, the clinical implications of hepatic steatosis are due mainly to its potential to cause chronic 
inflammation and then progress to cirrhosis and liver failure. 
One of the major causes of lipid accumulation in NAFLD is the inability of the liver to regulate 
changes in lipogenesis in the transition from fasted to fed state [5]. Several studies have suggested that 
hepatic lipogenesis is increased in hepatic steatosis, which may result from either increased 
triglyceride synthesis, or decreased fatty acid oxidation through production of malony-CoA, both 
leading to increased triglyceride content in the liver [6]. Excess fat accumulation ultimately leads to 
development of hepatic steatosis and worsening hepatic insulin resistance via a network of 
transcription factors [7], which regulate hepatic lipogenesis and fatty acid oxidation, including sterol 
regulatory element-binding protein-1c (SREBP-1c), liver X receptor, and peroxisome proliferator 
receptors (PPARs). In addition, normalizing serum lipids is also known to be a way to hinder the 
occurrence of hepatic steatosis. The potential lipid lowering effect might be mediated by down-regulation 
of various lipogenic enzyme activities. Enzymes of the lipogenic pathway that are transcriptionally 
regulated include acetyl-CoA carboxylase (ACC), fatty-acid synthase (FAS), diacylglycerol 
acyltransferase2 (DGAT2), and stearoyl-CoA desaturase (SCD-1).  
There has been a substantial effort toward understanding the mechanisms underlying NAFLD 
induced metabolic disorders and numerous studies have been conducted in the search for natural active 
Nutrients 2014, 6 2181 
 
products, particularly potential sources of antioxidant [8]. Bamboo has been used for medicinal 
purposes for centuries in Korea and other Asian countries, and its efficacy has been recorded in the 
materia medica, DongEuiBoGam in Korea [9,10]. Recent scientific research has demonstrated the 
health benefits of Bamboo leaves [10,11], culm [12], shoot [13], and shavings [14]. 
The medicinal effects of Sasa borealis, a species of Bamboo, are predominantly anti-diabetic 
through enhancement of insulin secretion [15], hypoglycemic and hypolipidemic effects [11],  
anti-obesity [16] and/or anti-oxidant effects [17]. In addition, clinical uses of Bamboo for treatment of 
hypertension, arteriosclerosis, cardiovascular disease, and cancer have been described [18].  
Currently, no studies investigating the effects of dietary supplementation with Sasa borealis stem 
(SBS) extracts on fat metabolism in a high-fat diet (HFD)-induced NAFLD model have been reported. 
In the current study, we investigated the effects of SBS on lipid levels and cholesterol levels in the 
liver and serum of rats fed a HFD, and on expression of genes involved in fatty acid synthesis and 
oxidation in the liver. 
2. Experimental Section  
2.1. Preparation of Sasa borealis Stem (SBS) Extracts 
Briefly, the stems of Sasa borealis were collected during the autumn season in Gyeongnam Province, 
Korea. The coarse powder of SBS was obtained after comminution and filtration (20–40 mesh) and 20 g 
powder were ground in an 80% (v/v) methanol solution using a mixer, followed by extraction of the 
samples for three days with vigorous shaking. The filtrate was then isolated by membrane filtration for 
removal of macro- and micro-molecular components, such as polysaccharides and minerals. The 
extraction yield from dry weight of SBS was 19.6%. The methanol extracts of the SBS were 
concentrated using rotary-vacuum evaporation at 50 °C and then freeze-dried. 
2.2. Measurement of Total Phenolic Content Using the Folin-Ciocalteu Assay 
The total phenolic content of the SBS was determined using a spectrophotometer according to the 
Folin-Ciocalteu colorimetric method [19]. Because gallic acid is one of the polyphenol compounds 
found in SBS, the total phenolic content of methanol extract of SBS was expressed as mg gallic acid 
(Sigma-Aldrich, USA) equivalents (GAE)/g.  
2.3. Measurement of Total Flavonoids  
The total flavonoid content was determined as previously described [20] with slight modifications. 
Briefly, 0.25 mL of SBS extracts (100 µg/mL) was added to a tube containing 1 mL of double-distilled 
water. Next, 0.075 mL of 5% NaNO2, 0.075 mL of 10% AlCl3, and 0.5 mL of 1 M NaOH were added 
sequentially at 0, 5, and 6 min. Finally, the volume of the reacting solution was adjusted to 2.5 mL 
with double-distilled water. The solution had an absorbance of 410 nm, which was detected using an 
Ultrospec 2100 Pro Spectrophotometer (Section 3.3). The results were expressed in mg quercetin 
equivalents (QE)/g. 
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2.4. Measurement of Free Radical Scavenging Activity Using the 2,2-Diphenyl-1-picrylhydrazyl 
(DPPH) Assay  
The free radical scavenging activity of SBS (100 µg/mL in DW) was measured using the method of 
Brand-Williams [21] with some modification. L-Ascorbic acid was used as a positive control. The 
inhibition percentage was calculated from the following equation:  
Inhibition% = [(absorbance of control-absorbance of sample)/absorbance of control] × 100 (1)
The absorbance was measured using a spectrophotometer (Ultrospec 2100 pro; Amersham 
Pharmacia Biotech Co., Piscataway, NJ, USA).  
2.5. Measurement of Hydroxyl (OH−) Radical Scavenging Activity 
Scavenging activity of SBS extracts on the hydroxyl radical (OH−) was measured using the 
deoxyribose method [22] with a slight modification. The deoxyribose assay was performed in  
10 mM phosphate buffer (pH 7.4) containing 2.5 mM deoxyribose, 1.5 mM H2O2, 100 μM FeCl3,  
104 μM EDTA, and the extracts (1 mg/mL). The reaction was started by addition of ascorbic acid to 
the final concentration of 100 μM. The reaction mixture was incubated at 37 °C for 1 h in a water-bath 
and after incubation, the color was developed by addition of 0.5% thiobarbituric acid followed by  
ice-cold 2.8% trichloroacetic acid in 25 mM NaOH and heated at 80 °C for 30 min. The extracts (A2) 
were cooled on ice and the absorbance was measured at 532 nm. The reaction mixture without the test 
sample was used as a control (A1). The hydroxyl radical scavenging activity (HRSA) was calculated 
using the following equation:  
HRSA% = (A1 − A2/A1) × 100 (2)
The inhibition curve was plotted for four experiments and was expressed as the % of the mean 
inhibition ±SD.  
2.6. Measurement of ABTS Radical Scavenging Activity  
ABTS radical scavenging activity of SBS extracts and fractions was measured using the ABTS 
cation decolorization assay, as previously described [23], with some modifications. The ABTS radical 
cation (ABTS•+) was produced by reaction of 7 mM stock solution of ABTS with 2.45 mM potassium 
persulfate and allowing the mixture to stand in the dark at room temperature for 12 h before use. The 
ABTS•+ solution was diluted with methanol to give an absorbance of 0.7 ± 0.01 at 734 nm. Plant 
extracts and fractions (1 mL) were allowed to react with 2 mL of the ABTS•+ solution and the 
absorbance was measured at 734 nm after 1 min. Trolox was used as a reference compound. The 
results were expressed as Trolox equivalent antioxidant capacity (TEAC) values and calculated as 
mean value ± SD (n = 4).  
2.7. High-Performance Liquid Chromatography (HPLC) Analysis of SBS Compounds 
Analysis of the compounds in the extract was performed using an Agilent 1100 series HPLC unit, 
equipped with a DAD. Samples were separated on a Nucleosil 100-5 C-18 column (250 mm × 4.0 mm, 
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i.d., 5 μm particle size) which was protected by a 10 mm guard column with a gradient elution system. 
The mobile phase consisted of two solvents: solvent A was a mixture of water/formic acid (pH 3.29), 
and solvent B was 100% acetonitril/formic acid (pH 3.29). Gradient elution was performed as follows: 
initially, 7.0% of solvent B, followed by 0% to 15% B in 25 min, 30% B at 35 min, 40% B at 50 min, 
100% B at 45 min, and 100% B at 55 min. The flow rate was 1.0 mL/min, and the column temperature 
was 30 °C. Used phenolic or flavonoid standard were performed by comparing retention times. The 
injections of sample and standard were performed in triplicate. 
2.8. Animals and Diets 
Four-week-old male Sprague-Dawley (Central Lab. Animal Inc.) rats were purchased from Central 
Lab. Animal Inc. (Seoul, Korea). Rats were acclimatized to the experimental facility for one week 
prior to the start of the study. The rats were divided into three groups of 10 and housed individually in 
polycarbonate cages in a room maintained at 22 °C and 55% relative humidity. The room was exposed 
to alternating 12 h periods of light and dark. All of the rats were allowed free access to food and water 
for five weeks. Food intake was measured daily, and the rats were weighed twice per week. After one 
week of acclimatization, rats were randomly divided into three groups: a normal diet group (ND, n = 10), 
a high-fat diet group (HFD, n = 10), and a SBS group (HFD + SBS 150 mg/kg BW, n = 10). Rats in 
the ND group were fed a normal diet (#55VXT0038, Samyang Co, Korea). Obese rats were generated 
by feeding rats a high-fat diet, and rats in the HFD groups were fed a HFD based on a commercial diet 
(rodent diet with 60% kcal fat, Research Diet, Korea). The composition of the diets and energy 
densities were presented in Table 1. The study protocol was approved by the Animal Care and Use 
Committee of Gyeongsang National University (Approval Number: GNU-130525-R0042). 
Table 1. Ingredient composition of the experimental diet. 
Ingredient (milligram) HFD HFD + SBS (mg/kg/day) 
Casein 200 200 
L-Cystine 3 3 
Maltodextrin 10 125 125 
Sucrose 68.8 68.8 
Cellulose 50 50 
Soybean Oil 25 25 
Lard 245 245 
Mineral Mix S10026 10 10 
DiCalcium Phosphate 13 13 
Calcium Carbonate 5.5 5.5 
Potassuium Citrate 16.5 16.5 
Vitamin Mix V10001 10 10 
Choline Bitartrate 2 2 
Protein (milligram%) 26.2 26.2 
Carbohydrate (milligram%) 26.3 26.3 
Fat (milligram%) 34.9 34.9 
SBS extracts -  150 
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2.9. Biochemical Analysis  
Biochemical analysis was performed using commercial kits. Blood was placed in tubes containing 
EDTA2Na, and serum was obtained by centrifuging the blood at 3000× g 10 min at 4 °C. Serum levels 
of aspartate aminotransferase (AST) and alanine aminotransferase (ALT) were detected using a  
Dry-chem Chemistry analyzer (Fujifilm, Japan). Excessive accumulation of triglyceride (TG) in the 
liver is the hallmark of NAFLD. Serum TG levels were assayed enzymatically using commercial kits 
(Asan phams, Co., Korea). For determination of hepatic TG content, 250 mg of liver was homogenized 
in 4 mL of chloroform/methanol (2:1, v/v), and 1 mL of 50 mM NaCl was added to each sample. The 
samples were then centrifuged, and the organic layer was removed and dried. The resulting pellet was 
dissolved in phosphate-buffered saline containing 1% Triton X-100, and the triglyceride content was 
determined using a commercially available enzymatic reagent kit (Asan phams, Co., Korea). The 
concentrations of total-cholesterol (TC) and high-density lipoprotein (HDL)-cholesterol were assayed 
enzymatically using commercial kits (Asan phams, Co., Korea). 
2.10. Histopathological Examinations  
Liver samples obtained at 12 h after the last administration of SBS extracts were fixed in 4% 
phosphate-buffered 4% Paraformaldehyde, then processed routinely, embedded in paraffin, and 
sectioned to 5 µm thickness. The sections were deparaffinized, rehydrated using standard techniques, 
stained with hematoxylin and eosin (H and E), and examined by light microscopy.  
2.11. Gene Expression Analysis  
Total RNA was isolated from liver tissues from the different rat groups using Trizol reagent 
(Invitrogen, CA, USA). One microgram of total RNA was subjected to first strand cDNA synthesis 
using oligo (deoxythymidine) primers and Superscript II reverse transcriptase (Invitrogen, CA, USA). 
The target cDNA was amplified using the following sense and antisense primers: sense 5′-GGA GCC 
ATGGATTGCACATT-3′ and antisense 5′-AGGAAGGCTTCCAGAGAGGA-3′ for SREBP-1c; sense 
5′-AAGGCTATCCCAGGCTTTGC-3′ and antisense 5′-CGTCTGACTCGGTCTTCTTG-3′ for PPARα; 
sense 5′-TTTTCAAGGGTGCCAGTTTC-3′ and antisense 5′-AATCCTTGGCCCTCTGAGAT-3′ for 
PPARγ; sense 5′-TGCTAGAGGCCCTGCTACCAC-3′ and antisense 5′-TGTGCACAGACACCTT 
CCCATC-3′ for FAS; sense 5′-AGGAAGATGGTGTCC CGCTCTG-3′ and antisense 5′-GGGG 
AGATGTGCTGGGTCAT-3′ for ACC; sense 5′-TACAAGCAGGTGATCTTTGAGG-3′ and 
antisense 5′-GGGCGAAACCAATATACTTCTG-3′ for DGTA2. Control detection of β-actin was 
performed using sense 5′-AGGTCATCACTATCGGCAAT-3′ and antisense 5′-ACTCATCGTACT 
CCTGCTTG-3′ primers. PCR products were separated by electrophoresis on 1.5% agarose gel for  
30 min at 100 V. Gels were stained with 1 mg/mL ethidium bromide visualized by UV light using 
BIO-RAD Gel Doc image analysis software (BIO-RAD Laboratories Inc., CA, USA). All PCR 
products measured were normalized to the amount of β-actin cDNA in each sample. The mPNA levels 
are expressed as a ratio relative to β-actin mRNA.  
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2.12. Statistical Analysis 
Data are expressed as mean ± SD. Significant differences among the treatment means were 
determined using ANOVA followed by Tukey’s multiple comparisons test. p < 0.05 was considered 
statistically significant. 
3. Results 
3.1. Total Phenol Content (TPC) and Total Flavonoid Content (TFC) of SBS Extracts 
Data from analysis of total phenolic and flavonoid contents in the methanol extract from SBS are 
shown in Table 2. The phenolic contents of the extracts are shown as (+)-catechin equivalents (CQ) 
and flavonoids as quercetin equivalents (QE). The total phenolic content was 430.3 mg CE/g dry 
weight and the total flavonoid content of SBS extracts was 127.5 mg QE/g dry weight, respectively 
(Table 2). 
Table 2. Antioxidant capacities, total phenolic and flavonoids content of Sasa borealis stem (SBS) extracts. 
 
TPC 











SBS 430.0 ± 40.2 127.5 ± 12.0 43.7 ± 2.3 450.5 ± 28.5 0.6 ± 0.05 
3.2. Antioxidant Activity of SBS Extracts  
The antioxidant activities of SBS extracts were determined using the DPPH, ABTS, and HRSA 
assays. Data on DPPH radical scavenging activity of SBS are shown in Table 2. The results were 
expressed as IC50, which indicates the antioxidant concentration necessary for scavenging the initial 
DPPH concentration by 50%. The SBS extract also inhibited hydroxyl radical generation and was 
found to possess strong antioxidant activity in hydroxyl radical scavenging activity. Trolox equivalent 
antioxidant capacity (TEAC) assay is one of the most commonly employed methods for determining 
antioxidant capacity. The TEAC assay measures the ability of a compound to scavenge ABTS radicals, 
and is widely used in screening of antioxidant activity of fruits, vegetables, and plants. The result of 
antioxidant activity of SBS extracts was expressed as TEAC values, as shown in Table 2. SBS showed 
high radical scavenging potential.  
TPC, total phenolic content; TPC, total flavonoid content. Data are presented as the mean ± SD  
(n = 4). TPC expressed as milligrams of gallic acid per gram of dry weight. TFC expressed as 
milligrams of Quercertin equivalent per gram of dry weight. Scavenging of free radicals by SBS 
extracts according to DPPH, Hydroxyl (OH−), and ABTS scavenging assay. DPPH, DPPH radical 
scavenging activity; ABST, ABST radical scavenging activity; HRSA, hydroxyl radial scavenging 
activity. Data are presented as mean ± SD (n = 4). The antioxidant activity was evaluated as the 
concentration of tested sample required to scavenge 50% of the DPPH and HRSA. Trolox equivalent 
antioxidant capacity (TEAC) assay measured the ability of SBS to scavenge ABTS radicals. SBS 
extracts also contained phloroglucinol, 4-hydroxy benzhydrazide, garlic acid, vanillic acid, caffeic 
acid, syringic acid, chlorogenic acid, p-coumaric acid, trans-ferulic acid, sinapic acid, 2-amino-3, 
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4-dimethyl-benzoic acid, protocatechuic acid, and coumarin. Among phenolic compounds, 
protocatechuic acid, coumarin, and p-coumaric acid were the main materials. In addition, SBS extracts 
also had many flavonoids, such as gallocatechin, epigallocatechin, catechin hydrate, epicatechin, 
epigallocatechin gallate, rutin hydrate, naringin, quercetin hydrate, myricetin, quercetin dehydrate, 
luteolin, and kaempferol (Table 3). 
Table 3. Concentrations of phenolic acids and flavonoids of SBS extracts. 
Standards RT 1 λ 2 Calibration curve LOQ 3 Compounds 
Phenolic acids 
Phloroglucinol 7.27 280 Y = 397.949X + 0.655 50.00 0.60 ± 0.00 
4-Hydroxy benzhydrazide derivative 7.57 280 Y = 8119.555X − 59.083 50.00 0.26 ± 0.00 
Gallic acid 8.74 280 Y = 18,200.182X − 28.003 50.00 0.53 ± 0.00 
Vanillic acid 21.91 280 Y = 11,026.185X + 14.026 50.00 1.44 ± 0.01 
Caffeic acid 22.21 280 Y = 19,697.774X − 13.018 50.00 0.74 ± 0.00 
Syringic acid 24.10 280 Y = 17,500.224X − 1.523 5.00 1.41 ± 0.01 
Chlorogenic acid 24.92 280 Y = 6240.064X − 10.524 50.00 1.61 ± 0.01 
p-Coumaric acid 32.87 280 Y = 23,926.358X + 0.631 5.00 10.41 ± 0.05 
trans-Ferulic acid 34.48 280 Y = 16,058.167X − 17.063 50.00 3.44 ± 0.02 
Sinapic acid 34.91 280 Y = 7025.930X + 0.785 50.00 2.98 ± 0.01 
2-Amino-3,4-dimethyl-benzoicacid 35.30 280 Y = 1209.000X + 0.000 50.00 6.95 ± 0.04 
p-Anisic acid 35.40 280 Y = 9558.576X + 5.493 50.00 -  
Protocatechuic acid ethyl ester 36.89 280 Y = 8796.340X − 2.765 50.00 13.05 ± 0.06 
Coumarin 38.27 280 Y = 24,055.754X + 48.641 4.00 14.91 ± 0.04 
DPBA 4 39.85 280 Y = 2971.415X − 7.872 50.00 - 
Alizarin 43.86 280 Y = 15,428.805X + 19.936 1.00 - 
Total phenolic acids 62.98 ± 0.08 
Flavonoids 
Gallocatechin 17.68 280 Y = 1331.637X + 0.000 50.00 1.59 ± 0.00 
Epigallocatechin 18.58 280 Y = 96.137X − 0.550 50.00 0.73 ± 0.00 
Catechin hydrate 23.66 280 Y = 3982.083X − 6.943 5.00 2.65 ± 0.01 
Epicatechin 28.00 280 Y = 7641.670X − 14.487 50.00 2.47 ± 0.00 
Epigallocatechin gallate 29.53 280 Y = 6425.894X − 6.592 50.00 0.98 ± 0.00 
Rutin hydrate 32.93 370 Y = 4763.242X − 4.752 50.00 0.29 ± 0.01 
Catechin gallate 33.77 280 Y = 1462.905X − 1.970 50.00 - 
Naringin 34.14 280 Y = 8230.457X − 42.997 50.00 2.60 ± 0.02 
Quercetin hydrate 37.53 370 Y = 7476.858X − 6.972 50.00 2.48 ± 0.02 
Myricetin 37.41 370 Y = 9908.955X − 0.383 5.00 0.43 ± 0.00 
Morin hydrate 38.48 320 Y = 4100.693X − 4.129 50.00 - 
Quercetin dehydrate 40.19 370 Y = 5623.574X − 0.729 50.00 1.93 ± 0.00 
Luteolin 40.28 370 Y = 12,303.249X − 8.820 50.00 6.32 ± 0.03 
Kaempferol 42.89 370 Y = 12,894.258X + 38.962 20.00 0.95 ± 0.03 
3-Hydroxyflavone 45.75 320 Y = 4687.303X + 0.191 50.00 - 
Total flavonoids 23.42 ± 0.09 
Table 3 expressed by the RT, λ, calibration curve, LOQ and detected compounds. 1 RT, retention time;  
2 λ, absorbance (nm); 3 LOQ, limit of quantitation; 4 DPBA, diphenylboric acid 2-aminoethyl ester. Data are 
presented as mean ± SD (n = 3).  
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3.3. Effect of SBS on Body Weight and Liver Weight in HFD-Fed Rats 
Body weight gain and food intake of animals fed the experimental diets are shown in Table 4.  
No significant difference in food intake was observed among the groups during the experimental diet 
period. Consumption of HFD (Table 1) for five weeks resulted in significantly increased body weight 
compared to the normal diet (ND). In contrast, rats fed a HFD supplemented with SBS extracts had 
30.5% lower body weights than rats fed a HFD alone. The mean liver weight in the HFD group was 
significantly increased compared to that of the ND group. However, the increases in mean liver weight 
in the HFD + SBS group were smaller than those in the HFD group (Table 4). Although administration 
of HFD was found to result in significant elevation of the liver weight of the HFD group compared to 
the ND group, treatment with SBS was found to result in strong attenuation of liver weight. 
Table 4. Effects of SBS on body and liver weights in high-fat diet (HFD)-fed rats. 
 ND HFD HFD + SBS 
Food intake (g/day) 12.03 ± 1.1 11.04 ± 1.6 11.44 ± 1.5 
Body weight    
Initial weight (g) 136.2 ± 4.3 135.5 ± 2.7 134.2 ± 3.7 
Final weight (g) 338.7 ± 16.8 447.3 ± 20.5 * 388.5 ± 15.5 # 
Weight gain (g/5 weeks) 202.5 ± 9.3 311.8 ± 16.3 * 254.3 ± 10.7 # 
Liver weight (g/5 weeks) 2.5 ± 0.2 3.8 ± 0.3 * 3.2 ± 0.3 # 
Rats fed a HFD were treated orally with SBS extracts at a dose of 150 mg/kg body weight. ND: normal diet 
group, HFD: High-fat diet group, HFD + SBS: High-fat diet plus SBS (150 mg/kg BW) group. Body weight 
was measured twice per week. The weight of the liver was calculated by dividing the liver tissue weight by 
body weight (liver tissue/body weight × 100). The values are expressed as the mean ± SD (n = 10). * p < 0.01 
compared to ND. # p < 0.05 compared to HFD. 
3.4. Effect of SBS on Serum Total Cholesterols and Triglyceride Levels 
To determine hepatic steatosis-preventing the effect of SBS on HFD-fed rats, the serum lipid levels 
were measured. The HFD group showed significantly elevated serum TG concentrations compared to 
the ND group (Figure 1A). Administration of SBS resulted in decreased serum TG by 35% compared 
with the HFD group (Figure 1A). In addition, we found that the TG levels in the SBS group were close 
to those in the ND group. The HFD group also showed significantly increased levels of TC relative to 
the ND group, while SBS caused a marked decrease in serum TC levels when compared to the HFD 
group. The serum HDL-cholesterol level was significantly increased in the HFD + SBS group, when 
compared with HFD alone (Figure 1A). For evaluation of liver function, ALT and AST activities were 
examined between groups. Significantly increased ALT levels were observed in the HFD group 
compared to the ND group, while treatment with SBS resulted in a marked decrease in the ALT level 
compared to the HFD group (Figure 1B). AST levels in rats supplemented with SBS were significantly 
lowered compared to those in the HFD group (Figure 1B). 
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Figure. 1. Effect of SBS on serum lipid contents in HFD-fed rats. (A) Serum TG and TC 
levels in rats fed a normal diet (ND), high-fat diet (HFD), and high-fat diet supplemented 
with SBS. Serum TG and TC levels were significantly reduced in rats treated with HFD + SBS 
compared to HFD. The values are expressed as the mean ± SD. * p < 0.05, ** p < 0.01.  
(B) Serum levels of AST and ALT of rats fed ND, HFD, and HFD + SBS. The values are 




3.5. Effects of SBS on Hepatic Total Cholesterols Levels and Triglyceride Levels 
To examine the effect of SBS on biochemical changes, we determined the levels of TG and TC in 
the liver. Administration of a HFD was found to result in significantly increased hepatic TG and TC in 
the HFD group. The SBS group, treated with SBS, showed markedly lower levels of TG and TC in the 
liver (Figure 2A). In addition, after a HFD for five weeks, the hepatic HDL-cholesterol levels showed 
a decrease compared with the ND group. However, the hepatic HDL-cholesterol levels in the SBS 
group increased by approximately 40% compared with the levels from rats on a HFD (Figure 2A). 
These results can be attributed to the ability of SBS to effectively suppress accumulation of hepatic TG 
and TC in HFD-fed rats. 
3.6. Effects of SBS on Hapatic Steatosis 
Next, H and E staining was performed for analysis of the effect of SBS on HFD-induced lipid 
accumulation in the liver. Lipid accumulation was highly amplified in the HFD group compared to the 
ND group. Histological examination of livers also revealed significant hepatic steatosis-characterized 
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by swelling of hepatocytes and fat accumulation—in rats fed a HFD as compared with the HFD + SBS 
groups (Figure 2B). However, the lipid accumulations induced by HFD were significantly reduced in 
the HFD + SBS group, indicating that SBS is capable of preventing lipid accumulation and hepatic 
steatosis in HFD-induced fatty liver.  
Figure 2. SBS reduces hepatic lipid levels in HFD-induced hepatic steatosis in rats.  
(A) Hepatic TG and TC levels in rats fed a normal diet (ND), high-fat diet (HFD), and 
high-fat diet supplemented with SBS. Significant decreases in the levels of hepatic 
triglyceride and total cholesterol were observed in the SBS-treated groups compared with 
HFD-induced obese rats. Values are expressed as mean ± SD. * p < 0.05, ** p < 0.01.  
(B) Representative histological section of H & E staining of liver prepared from rats fed 
ND, HFD, and HFD supplemented with SBS (magnification 200×, scale bar = 100 µm). 




3.7. Effects of SBS on Hepatic mRNA Levels of Lipid-Related Gene Expression 
For evaluation of the molecular events underlying the effects of SBS, we analyzed the expression of 
genes involved in lipid homeostasis in the liver. We assessed hepatic levels of lipogenesis-related 
genes (SREBP-1c, PPARγ, and FAS), as well as fatty acid metabolism-related genes (PPARα, ACC, 
and DGAT2) in HFD-fed rats. According to our results, significantly lower gene expression levels of 
SREBP-1c, PPARγ, and FAS, which promote synthesis of de novo monounsaturated fatty acid, were 
observed in the SBS-treated group than in the HFD group (Figure 3). Of these genes, expression of 
SREBP-1c and PPARγ showed the most significant reduction in the SBS group, compared to the HFD 
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group (Figure 3). Hepatic mRNAs for PPARα and ACC, the genes involved in fatty acid β-oxidation, 
were significantly decreased by BS administration when compared to the HFD group. In addition, SBS 
supplementation induced a significant decrease in the mRNA level of DGAT2 compared to the HFD 
group (Figure 3). Together, these results demonstrated that SBS contributed to inhibition of fatty acid 
synthesis, while activating fatty acid β-oxidation in livers of HFD-fed rats.  
Figure 3. SBS inhibits expression of genes that regulate hepatic lipogenesis and fatty acid 
oxidation in hepatic steatosis. Total RNA isolated from liver was subjected to RT-PCR, 
and all of the gene transcripts were normalized using β-actin as a control. All of the 
experiments were performed in three independent experiments. Mean valves were 
significantly different from the ND group: * p < 0.05; ** p < 0.01; and *** p < 0.001.  
ND, rats fed a normal diet; HFD, rats fed a high-fat diet; HFD + SBS, rats fed a high-fat 
diet plus SBS (150 mg/kg BW); SREBP-1c, sterol regulatory element-binding protein-1c; 
PPARα, peroxisome proliferator receptors-alpha; PPARγ, peroxisome proliferator 
receptors-gamma; FAS, fatty-acid synthase; ACC, acetyl-CoA carboxylase; DGTA2, 
diacylglycerol acyltransferase 2. 
 
4. Discussion  
Despite the rapidly growing recognition of hepatic steatosis over the past decade, therapy directed 
at treatment or prevention of the disease remains. Given the high prevalence of obesity in patients with 
hepatic steatosis, prevention of hepatic fat accumulation through weight reduction remains the 
cornerstone of treatment of hepatic steatosis [24]. In the current study, we investigated the anti-hepatic 
steatosis activity of SBS extract in HFD-fed rats. Our results demonstrated that, compared to the ND 
group, noticeably greater lipid accumulation in liver tissue and dramatically increased body and liver 
weights were observed in the HFD group. However, SBS supplementation in rats fed a HFD was 
effective in decreasing liver triglyceride and total cholesterol, and resulted in marked lowering of liver 
weight increases compared to the HFD group.  
High fat diets cause weight gain, fat accumulation, and increased fat levels in the liver and serum. 
Fat accumulation in the liver increases the risks of NAFLD and non-alcoholic steatohepatitis (NASH), 
which cause hypercholesterolemia and cardiovascular disease [25]. Regarding the changes in lipid 
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metabolism caused by fat accumulation, the aminotransferase activity of the liver is altered. 
Measurement of liver damage caused by fat accumulation in the liver is important for diagnosis of 
NAFLD. Therefore, AST and ALT were investigated as markers of liver damage. In the current study, 
levels of aspartate aminotransferase (AST) and alanine aminotransferase (ALT) showed a more 
significant increase in rats fed a HFD, compared to rats fed a ND. However, SBS supplementation 
resulted in significantly decreased levels of ALT and AST, demonstrating the robust hepatoprotective 
effects of SBS against HFD-induced liver damage.  
Obesity causes altered function of adipocytes, which leads to expanded adipocyte mass and 
increased release of FFAs in the blood, which increases the amount of TG stored in the liver. Excess 
storage of TG in the liver results in significant and more abundant lipid accumulation, resulting in fatty 
liver [26,27]. In this study, rats in the HFD group showed a large number of lipid droplets and 
increased TG and cholesterol concentration in the liver and serum, confirming development of hepatic 
steatosis in the animal model. Administration of SBS to rats fed a HFD resulted in significantly 
decreased body weight as well as liver tissue weight. Treatment with SBS also resulted in a significant 
decrease in the hepatic and serum TG concentrations in HFD-induced hepatic steatosis in rats. In 
addition, our data from histopathological examination of livers from the rats showed a significant 
increase in the number and size of fatty hepatocytes upon HFD administration but returned to normal 
levels in rats that were administered SBS. These results demonstrated that the HFD-induced hepatic 
pathological changes were significantly inhibited in SBS-fed rats. These results clearly demonstrated 
that treatment with SBS resulted in effective improvement of hepatic steatosis induced by HFD. 
The chemical compound cholesterol is a combination of lipid and steroid and is produced naturally 
by the body. Approximately 80% of the body’s cholesterol is produced by and stored in the liver [28]. 
The liver is able to regulate cholesterol levels in the bloodstream and can secrete cholesterol if it is 
needed by the body. In the current study, we showed that administration of a HFD resulted in 
significantly increased levels of TC and decreased levels of HDL-cholesterol in serum and liver. 
However, administration of SBS resulted in decreased levels of serum and liver TC compared to the 
HFD group. In addition, SBS-fed rats showed liver HDL-cholesterol levels similar to those of  
the ND group.  
Next, to explore the possible mechanism of SBS in decreasing accumulation of liver lipids, we 
investigated the expression levels of several genes related to fatty acid transport, and lipid metabolism, 
including lipogenesis and β-oxidation. Several studies have demonstrated the important role of 
SREBP-1c, a major transcription factor involved in hepatic lipogenesis, which leads to increases in 
fatty acid synthesis as a result of the induction of FAS and ACC [29,30]. One study reported that the 
level of SREBP-1c showed positive correlation with the degree of hepatic steatosis in patients with 
NAFLD [31]. Results of the current study showed that the level of SREBP-1c was significantly higher 
in the liver of rats fed a HFD compared with that of ND rats. However, SBS effectively inhibited the 
raise of SREBP-1c expression. FAS catalyzes the late step in fatty acid biosynthesis, thus, it is believed 
to be a major determinant of maximal hepatic capacity for generation of fatty acids by de novo 
lipogenesis. According to these results, administration of SBS resulted in decreased HFD-induced high 
expression of ACC and FAS, and expression of SREBP-1c transcriptional targets FAS and ACC 
showed strong correlation with SREBP-1c expression, suggesting that suppression of ACC and 
expression of FAS may contribute to a reduction in lipid accumulation in fatty liver. Together, since 
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SBS supplementation in HFD rats resulted in significantly reduced serum and hepatic triglyceride, and 
cholesterol concentrations, these results demonstrated that SBS induced down-regulation of 
lipogenesis-related genes in HFD-induced fatty liver. Of particular importance, PPARα is a  
ligand-activated transcription factor; its activation induces the mRNA expression of several genes 
involved in fatty acid oxidation to reduce the circulating lipid levels [32]. The current results showed 
significantly lower PPARα expression in the HFD group than in the ND group, and it was increased by 
BS supplementation. Findings of a recent report indicated that PPARα also modulates hepatic 
lipogenic gene expression, such as DGAT, ACC, and PGC-1α, which are closely related to fatty acid 
synthesis and oxidation in hepatic steatosis in HFD-fed animals [33]. DGAT is a microsomal enzyme 
that joins acyl-CoA to 1,2-diacylglycerol and thus constitutes the final step in TG biosynthesis [34]. 
Our results showed that DGAT2 expression in HFD rats was significantly increased, while DGAT2 
mRNA expression showed a dramatic decrease in the SBS-treated group. Recent studies have 
suggested that overexpression of DGAT2 leads to increases in large cytosolic lipid droplets [34], and 
hepatic-specific overexpression of DGAT2 led to increased liver TG content [35]. Therefore, our 
results indicated that administration of SBS resulted in down-regulation of the levels of DGAT2 
mRNA and reduction of DGAT2 expression in the HFD-SBS group inhibited accumulation of hepatic 
lipid droplets via a decrease of TG synthesis. In the current study, we also found that mRNA 
expression of PPARγ was significantly lower in the FHD-SBS group than in the HFD group, 
demonstrating that a SBS-supplemented diet induced a reduction of PPARγ expression in the  
HFD-induced steatosis liver. In addition, gene expression generally exhibits a negative relationship 
with the DNA methylation of CpG islands in the gene promoter region. Sookoian et al. [36] reported 
that an increase of PPAR-γ coactivator 1α methylation correlated with decreased mRNA expression in 
the liver and contributed to insulin resistance in NAFLD patients. In HFD-fed mice, the increased 
methylation of the PPARγ promoter accompanied by the decreased expression of PPARγ mRNA in 
visceral adipose tissues was associated with the pathogenesis of metabolic syndrome [37]. Taken 
together, our results showed a significantly smaller liver lipid droplet area in the SBS group, 
accompanied by an increase in PPARα and a decrease in expression of SREBP-1c, FAS, ACC,  
and DGAT2. 
Medicinal plants or many natural products exhibiting good antioxidant activity are associated with 
hepatoprotection potential. Bamboo leaves exhibited significant antioxidant activity against the  
1,1-diphenyl-2-picrylhydrazyl (DPPH) radical and a cytoprotective effect against oxidative damage in 
liver cells [17]. In the current study, we found that SBS extracts contained high phenolic contents  
(430 mg gallic acid equivalent/g extract) and flavonoid contents (127.5 mg quercetin equivalent/g extract), 
respectively. When we analyze SBS extracts using with HPLC-DAD, in terms of phenolic acids, SBS 
extracts had phloroglucinol, 4-hydroxy benzhydrazide, garlic acid, vanillic acid, caffeic acid, syringic 
acid, chlorogenic acid, p-coumaric acid, trans-ferulic acid, sinapic acid, 2-amino-3,4-dimethyl-benzoic 
acid, protocatechuic acid, and coumarin. Among phenolic compounds, protocatechuic acid, coumarin, 
and p-coumaric acid were the main materials. In addition, SBS extracts also had many flavonoids, such 
as gallocatechin, epigallocatechin, catechin hydrate, epicatechin, epigallocatechin gallate, rutin hydrate, 
naringin, quercetin hydrate, myricetin, quercetin dehydrate, luteolin, and kaempferol. Our results also 
showed that SBS had an effective capacity of scavenging for DPPH, ABTS, and hydroxyl radicals and 
showed correlation with potent phenol and flavonoid contents, thus, suggesting its antioxidant 
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potential. The current finding suggested that hepatoprotective effects and anti-steatosis functions of 
SBS in HFD-induced NAFLD may be due to the potent antioxidant properties and to the abundant 
presence of phenolic and flavonoid contents of SBS.  
5. Conclusions 
In conclusion, these results indicated that SBS induced significant suppression of TG and cholesterol 
accumulation in the liver of rats fed a HFD. SBS possesses a repressive property on hepatic steatosis, 
which is associated with inhibition of SREBP1c, PPARγ, ACC, DGAT2, and FAS, and induction of 
PPARα, suggesting a potential application of SBS in treatment of HFD-induced NAFLD.  
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